Atrix and Geneva Pharmaceuticals join forces on prescription generics development

Atrix Laboratories Inc. (Fort Collins, CO) and Novartis subsidiary Geneva Pharmaceuticals Inc. (Denver) have agreed to codevelop and manufacture prescription generic dermatology products. The alliance has targeted a number of products to develop over a ten-year period. Geneva will market the products developed by Atrix under a profit sharing agreement.

Atrix has a rich product pipeline that is well balanced over preclinical testing through market. Its deal with Geneva focuses on relatively early-stage dermatology products.

Said David R. Bethune, chairman and CEO of Atrix, "This is exactly the kind of collaboration that was envisioned when we set up our dermatology business unit. Aggregate sales of the branded product families targeted for development represents about $1 billion in combined U.S. sales and yet none have been marketed as a generic."

Atrix certainly has the scientific expertise and the manufacturing skill to get dermatological products to market. Geneva, a top generic pharmaceutical firm, is the ideal marketing partner.

For more information: Danette R.M. Meyer, Director of Investor Relations, Atrix Laboratories, 2579 Midpoint Dr., Fort Collins, CO 80525-4417. Tel: 970-482-5868. Fax: 970-482-9735.

Edited by Angelo DePalma
Managing Editor, Pharmaceutical Online and Drug Discovery Online
Email: adepalma@vertical.net